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Abstract
Atherosclerosis is promoted by a combination of hypercholesterolemia and vascular inflammation.
The function of Angiopoietin-2 (Ang-2), a key regulator of angiogenesis, in the maintenance of large
vessels is unknown. A single systemic administration of adenoviral Ang-2 (AdAng-2) to apoE-/- mice
fed a Western diet significantly reduced atherosclerotic lesion size (~40%) and oxidized LDL and
macrophage content of the plaques. Nitric oxide (NO) synthase (NOS) inhibitor abolished these
beneficial effects of Ang-2. In endothelial cells, eNOS activation per se inhibited LDL oxidation and
Ang-2 stimulated NO release in a Tie2-dependent manner to decrease LDL oxidation. These findings
demonstrate a novel atheroprotective role for Ang-2 where endothelial cell function is compromised
and suggest that growth factors, which stimulate NO release without inducing inflammation, could
offer atheroprotection.
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Introduction
The endothelium plays a vital role in the prevention of atherosclerosis, yet the molecular
mechanisms that confer atheroprotection are poorly understood.1 Angiopoietin-2 (Ang-2), a
context-dependent agonist/antagonist for the Tie2 receptor, promotes vascular regression or
facilitates vascular endothelial growth factor (VEGF)-driven angiogenesis.2 Despite the
extensive studies of Ang-2 in the microvasculature, its role in atherosclerosis is unknown.
Ang-2 in high concentrations induces robust phosphorylation of Tie23 and prevents endothelial
cell apoptosis4 through activation of the pro-survival Akt pathway, which can phosphorylate
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eNOS.4, 5 Stressed endothelial cells express high levels of Ang-2, which acts as an autocrine
Tie2 agonist to bolster Akt activity.6 As loss of eNOS activity is an established contributor to
endothelial dysfunction7 and endothelium-derived NO plays a vital role in the prevention of
atherosclerosis,8 we explored whether Ang-2 could suppress atherosclerosis by stimulating
NO release in apoE-/- mice. In this report we show that overexpression of Ang-2 reduces lesion
size, macrophage accumulation and oxidized LDL content of plaques in atherosclerosis-prone
apoE-/- mice. The protective effect of Ang-2 was abolished by NOS inhibition. Our
investigation demonstrates a novel function for Ang-2 as an atheroprotective mediator, which
inhibits atherosclerosis through the activation of eNOS to reduce LDL oxidation.
Material and methods
The expanded Materials and Methods section in the online supplement, available at
http//:circres.ahajournals.org provides a description of the apoE-/- mouse model of
atherosclerosis, adenoviruses, immunohistochemical, NO and LDL oxidation methods.
Results and Discussion
Ang-2 suppresses atherosclerosis in apoE null mice
After three weeks on a Western diet, eight-week old apoE-/- mice received a single systemic
administration of Ang-2 adenovirus (AdAng-2; 1.0 × 1010 pfu) or control adenovirus (AdEV)
and sacrificed four weeks later. All mice developed atherosclerotic lesions along the proximal
aortic wall and at the valve cusps. Circulating levels of Ang-2 were detected only in the
AdAng-2-treated group (mean ± SD 12.8 ± 5.6 μg/ml; Online Figure I), and there were no
significant differences in the body weight or plasma lipid levels between the two groups (Online
Table I). These findings suggest that the beneficial effect of Ang-2 was not due to suppression
of appetite. AdAng-2-treated mice showed a highly significant reduction in atherosclerotic
plaque lesion size compared with control mice receiving AdEV (0.269 ± 0.04 mm2 vs. 0.437
±0.05 mm2; n=10/group; P< 0.01; Figure 1A). Lesion size in a separate group of uninfected
animals (0.547±0.05 mm2; n=3) was similar to AdEV-treated mice indicating that adenoviral
infection per se did not increase atheroclerosis. Histological analysis revealed a decrease in
CD11b-positive macrophages/monocytes (Mø) in the plaque (middle panel, Figure 1B).
Immunohistochemical analysis of malondialdehyde–lysine (MDA2), a marker of oxidized
LDL,9 revealed reduced oxidized LDL staining in aortic sections of AdAng-2-treated animals
(bottom panel, ox-LDL, Figure 1B). Staining for CD31 showed that the aortic endothelium
remains intact in the AdAng-2 treated mice. This is in marked contrast to the effect of Ang-2
promoting endothelial cell detachment reported in a three-dimensional culture model.10 It is
possible that acute effects of Ang-2 may be deleterious, but long-term treatment may be
protective. Indeed, prolonged exposure of endothelial cells to Ang-2 induces a robust
phosphorylation of Tie2,3 a key pro-survival signal.6
Ang-2 induces NO release from endothelial cells
Stimulation of human umbilical vein endothelial cells (HUVEC) with Ang-2 resulted in a
concentration-dependent release of NO (Figure 2A), which was inhibited by Tie2 neutralizing
antibodies and a Tie2 blocking peptide (Figure 2B) demonstrating this effect is Tie2-dependent.
Although VEGF and Ang1 can induce NO release,11 both can recruit inflammatory cells12,
13 In addition, VEGF increased plaque formation double deficient apoE/apoB100 mice,14 and
Ang-1 failed to protect against the development of rat cardiac allograft arteriosclerosis.15 This
paradox may be explained by the fact that unlike VEGF and Ang-1, Ang-2 has little effect on
monocyte migration (Online Figure II). This ability of Ang-2 to stimulate NO release without
promoting inflammatory cell recruitment gives it the characteristics of an atheroprotective
factor.
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Ang-2 inhibits endothelial-mediated LDL oxidation
Oxidized LDL reduces endothelial function,16 however, it is unknown whether NO per se can
inhibit LDL oxidation in a cellular context. Therefore, we assessed NO production and LDL
oxidation in porcine aortic endothelial cells (PAEC) expressing constitutively active
eNOSS1177D (PAEC/eNOSS1177D) or control cells (PAEC/pcDNA) using thiobarbituric acid
reactive substances (TBARS) assay. PAEC/eNOSS1177D produced significantly more NO
(Online Figure IIIA) and reduced LDL oxidation compared with control cells (Online Figure
IIIB, P <0.01); an effect that was prevented by NOS inhibition indicating that NO inhibits
cellular LDL oxidation.
The observed reduction in tissue LDL oxidation in Ang-2-treated animals prompted us to
examine whether Ang-2 could suppress LDL oxidation by endothelial cells in vitro. In the
absence of cells, native LDL oxidation was low (16.9 ± 4.8 nmol TBARS/mg) whereas in the
presence of HUVEC, LDL oxidation increased significantly (49.5 ± 2.75 nmol TBARS/mg;
Figure 2C). Ang-2 dramatically inhibited LDL oxidation in HUVEC as demonstrated by a 57%
reduction in the formation of TBARS (23.5 ± 4.7 nmol TBARS/mg; p<0.01, n=4; Figure 2C),
which was partially abolished by L-NAME. The relative electrophoretic mobility of modified
LDL was used to confirm these findings (Figure 2D). In contrast to Ang-2, Ang-1 had no effect
on LDL oxidation (Online Figure IV). These results demonstrate that the antiatherogenic
property of Ang-2 may, in part, be due to its ability to inhibit LDL oxidation via a NO-
dependent mechanism.
Ang-2-mediated atheroprotection is NO-dependent
To investigate if the protective effect of Ang-2 in apoE-/- mice requires NO, L-NAME was
administered in the drinking water one day after adenoviral injection. In the absence of L-
NAME, AdAng-2-treated mice demonstrated a significant reduction in lesion area compared
with AdEV-treatment (0.141 ± 0.01 mm2 vs. 0.222 ± 0.03 mm2; n=8-10/group; P< 0.01; Figure
3A) as before (Figure 1). Inhibition of NOS had no significant effect on lesion size in AdEV-
treated mice but abrogated the beneficial effects of Ang-2 (Figure 3B). Furthermore, AdAng-2
significantly decreased MOMA-2-positive macrophages in the lesions, an effect that was also
inhibited by L-NAME (Figure 3A and C). Although lesion size was only quantified
histologically without supporting en face staining, these results demonstrate that the effects of
Ang-2 on lesion size were reproducible demonstrating the utility of this method for
quantification of these early stage lesions.
Taken together, this study demonstrates that NO per se suppresses LDL oxidation and Ang-2
inhibits atherosclerotic lesion development, in part, by reducing LDL oxidation and
macrophage accumulation via endothelial NOS activation. These results are consistent with
the contextual and concentration-dependent nature of Ang-23, 6 and indicate that Ang-2 may
offer atheroprotection in a hypercholesterolemic environment when endothelial cell function
is compromised. It will be important to establish whether the protective effects of the transient
high circulating levels of Ang-2 observed in early atherosclerotic lesions persist and can be
translated into long-term benefit.
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Figure 1. Ang-2 reduces atherosclerotic plaque formation, LDL oxidation and macrophage
accumulation in apoE-/- mice
ApoE-/- mice maintained on a Western diet were administered AdAng-2 or control empty virus
(AdEV). A, Atherosclerotic lesions in the aortic valves were stained with oil red O and the
results expressed as the mean plaque area ± SEM. Ang-2 significantly reduced the mean plaque
area (*P <0.01) compared with AdEV-treated apoE-/- mice. B, Immunohistochemical analysis
showed that CD31-positive endothelium (EC) remained intact, and CD11b-positive
macrophages (Mø) and malondialdehyde–lysine/MDA2 (ox-LDL) staining was reduced in
Ang-2 treated mice.
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Figure 2. Ang-2 suppresses LDL oxidation and stimulates NO release via Tie2 activation
A, Ang-2-mediated NO release in HUVEC was inhibited by 0.5 mM NG-nitro-L-arginine (L-
NNA). B, HUVEC were pretreated with either Tie2 (anti-Tie2; 5 μg/ml), or Tie1 (anti-Tie2;
5 μg/ml) neutralizing antibodies or Tie2 blocking peptide (Tie2 peptide; 0.5 mM) prior to
incubation with Ang-2 (400 ng/ml) for 1 hour and NO release quantified. Results are the mean
(±SEM) of three independent experiments (n = 9). C and D, HUVEC were incubated in serum-
free medium containing 100 μg/ml LDL, 500 ng/ml of Ang-2 and/or 100 μM L-NAME for 16
hours. Oxidative modification of LDL was assessed using: C, TBARS assay (data represents
the mean ± SEM; *P <0.01 vs. control, #P<0.05 vs. HUVEC+Ang-2 without L-NAME) and
D, the relative electrophoretic mobility of LDL.
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Figure 3. Ang-2-mediated reduction in atherosclerotic plaque formation requires NO
One day after administration of adenovirus, apoE-/- mice were treated with L-NAME. A,
Representative images of plaques stained for neutral lipids (oil red O) and macrophage
(MOMA-2) content. Quantification of B, mean plaque and C, MOMA-2 positive areas show
that the atheroprotective effect of AdAng-2 is abolished following L-NAME treatment. Data
are the mean area ± SEM; *P <0.01 vs. AdEV without L-NAME, §P<0.05 and #P<0.01 vs.
AdAng-2 without L-NAME.
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